Abstract (R)-Salsolinol (SAL), a dopamine (DA)-related tetrahydroisoquinoline, has been found in extracts of the neuro-intermediate lobes (NIL) of pituitary glands and in the median eminence of the hypothalamus obtained from intact male rats and from ovariectomized and lactating female rats. Moreover, analysis of SAL concentrations in NIL revealed parallel increases with plasma prolactin (PRL) in lactating rats exposed to a brief (10 min) suckling stimulus after 4-h separation. SAL is sufficiently potent in vivo to account for the massive discharge of PRL that occurs after physiological stimuli (i.e. suckling). At the same time, it was without effect on the secretion of other pituitary hormones. It has been also shown that another isoquinoline derivative, 1-methyldihydroisoquinoline (1MeDIQ), which is a structural analogue of SAL, can dose-dependently inhibit the in-vivo PRL-releasing effect of SAL. Moreover, 1MeDIQ can inhibit the elevation of plasma PRL induced by physiological stimuli, for example suckling, or in different stressful situations also. 1MeDIQ also has a psycho-stimulant action, which is fairly similar to the effect of amphetamine, i.e. it induces an increase in plasma catecholamine concentrations. It is clear from these data that this newly discovered endogenous compound could be involved in regulation of pituitary PRL secretion. It has also been observed that SAL is present in peripheral, sympathetically innervated organs, for example the atrium, spleen, liver, ovaries, vas deferens, and salivary gland. Furthermore, SAL treatment of rats results in dosedependent and time-dependent depletion of the DA content of the organs listed above without having any effect on the concentration of norepinephrine. More importantly, this effect of SAL can be completely prevented by amphetamine and by 1MeDIQ pretreatment. It is clear there is a mutual interaction between SAL, 1MeDIQ, and amphetamine or alcohol, not only on PRL release; their interaction with catecholamine ''synthesis/metabolism'' of sympathetic nerve terminals is also obvious.
role in the regulation of immune function [6, 7] , therefore PRL may participate in the development of immune tolerance between the fetus and the maternal organism during pregnancy [8] . There is a brief and sudden elevation of PRL during orgasms [9] . Therefore, PRL may also be involved in the ''gratification'' during sexual acts. PRL stimulates proliferation of oligodendrocyte precursor cells (these are cells that differentiate into oligodendrocytes), the cells that are responsible for formation of the myelin coating on axons in the central nervous system (CNS) [10, 11] . PRL contributes to surfactant synthesis of fetal lungs at the end of pregnancy [12] .
Basal secretion of PRL from the AL is spontaneous (i.e. occurs without stimulation by the hypothalamus [3] ) because PRL is secreted from mammotropes with a high secretory rate for prolonged periods after isolation from the effect of the hypothalamus (e.g. when transplanted to a site distant from the hypothalamus under the kidney capsule or when cultured in vitro). Consequently, PRL secretion seems to be severely restrained by the hypothalamus in vivo. The established hypothalamic hypophysiotrophic inhibitor of PRL secretion is dopamine (DA) produced by the arcuate-periventricular nucleus ( Fig. 1) , which travels from the median eminence (ME) to the AL via the long portal vessels [3] . Early studies, however, failed to account for an important source of DA reaching the AL through the short portal vessels from the neurointermediate lobe (NIL) (Fig. 1) . It is well known that hypophysiotrophic DAergic neurons in the hypothalamus consist of at least two different parts. Tuberoinfundibular DAergic (TIDA) neurons, located mainly in the middle and posterior portion of the arcuate nucleus projecting to the ME, are well accepted as a physiological regulator of adenohypophysial PRL secretion [3] . Evidence has also been presented that DA derived from the tuberohypophysial DAergic (THDA) system is also an important regulator of PRL secretion [3] . THDA neurons originate in the arcuate nucleus as do those of the TIDA. However, neurons of this system are located in the most rostral part of the arcuate and periventricular nucleus and terminate in the NIL of the pituitary gland rather than in the ME of the hypothalamus [3] . Therefore, DA released by THDA terminals would not be present in pituitary stalk blood, i.e. DA concentrations reaching the AL may have been underestimated. Indeed, removal [13, 14] or denervation [15] of the NIL elevates basal PRL secretion. Consistent with this finding is the observation that electrochemically detectable DA in the AL is reduced after surgical removal of the NIL [16] . Thus, DA of hypothalamic origin, which is delivered to the AL by way of the long and the short portal vessels (from TIDA or THDA, respectively) seems quantitatively sufficient to account for inhibition of PRL release [2, 3] .
Despite extensive supportive evidence for this ''simplistic'' view of the regulation of PRL secretion, it has been proved to be incomplete. For example, an inverse relationship does not always exists between release of hypothalamic DA and pituitary PRL secretion, for example, DA levels in hypophysial stalk plasma are a factor of 5-7 lower Fig. 1 Diagram of the hypothalamic dopaminergic (DAerg) systems that can regulate PRL secretion from the anterior lobe (AL). DA neurons originate from the arcuate nucleus, and they have short axons that terminate in the external zone of the median eminence (ME) near the primary capillary plexus of the portal vessels. The released DA is carried out by the long portal vessels to the anterior lobe (AL) of the pituitary. Exogen and endogen stimuli that can affect hypothalamic neurons are also highlighted. DA neurons of the hypothalamus can also produce salsolinol (SAL) that has an opposite, i.e. stimulatory, effect on PRL secretion Reprod Med Biol in males than in females [17] [18] [19] [20] but plasma levels of PRL are not much different. A lack of mirror image relationship between DA concentration of the ME and plasma PRL has also been demonstrated in lactating rats during simulated suckling stimulus [21] [22] [23] . In parallel with the classical view of hypothalamic tonic inhibitory control of PRL secretion, several exteroceptive stimuli, for example suckling of the nipples of lactating mothers by their litters, sharply elevate plasma PRL [3, 24] . This may be because of increased secretion of a PRL-releasing factor (PRF) [3, 25] and/or a concomitant decrease of the inhibitory effect of the hypophysiotrophic DA [13, 15, 26, 27] .
ANTERIOR LOBE (AL)
Candidates for the role of physiological PRFs are numerous. For example, hypothalamic thyrotropin-releasing hormone (TRH) is known from its thyroid stimulating hormone (TSH) releasing activity, but it has a strong stimulatory effect on PRL release, especially in vitro. Estrogen is also a key stimulatory regulator of PRL production. Moreover, it strongly enhances proliferation of PRL-producing cells and stimulates PRL production directly at the level of the pituitary gland and by suppression of DAerg tone exerted by the hypothalamus.
In the 1980s, several observations suggested that a new and possible authentic PRF may exist in the NIL [13] [14] [15] . Isolation of such a releasing factor has been suspected for almost two decades [3, 25] . Analysis by high performance liquid chromatography coupled with electrochemical detection (HPLC-EC) revealed the presence of the (R) enantiomer of salsolinol (SAL) in extracts of the NIL of pituitary glands and in the median eminence (ME) of the hypothalamus from intact male rats and from ovariectomized (OVX), OVX ? estradiol (E2) substituted, and lactating female rats (Fig. 2a ).
Structure and function of salsolinol SAL (1 methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline) was discovered in 1973 by Sandler et al. [28] . As can be seen in Fig. 3 , it belongs to a family of compounds Fig. 3 Structure of 1,2,3,4-tetrahydro-6,7-dihydroxy-1-methylisoquinoline (salsolinol, SAL) and 1-methyl-3,4-dihydroisoquinoline (1MeDIQ) and the enzymatic and non-enzymatic synthetic pathways of SAL from DA referred to as tetrahydroisoquinolines (TIQs). Several TIQs have mainly been regarded as potential neurotoxins in the meso-striatal DAerg system [29] . SAL is a DA-derived compound. It has an asymmetric center at first position and exists as (R) and (S) enantiomers. SAL can be formed in vivo through a non-enzymatic ring cyclization of DA with acetaldehyde. Peripherally administered SAL cannot cross the blood-brain barrier [30, 31] . SAL can be produced in different DAerg brain areas [32] including in the hypothalamo-hypophysial system (Fig. 2a) , namely at the terminal sites (ME and NIL) of the hypothalamic neuroendocrine DAerg (NEDA) neurons [25, 33] . SAL can also be synthesized enzymatically by an already purified but still not sequenced enzyme, so called SAL-synthase [25, 33] . As was remarked in the previous section, SAL is likely to act as an endogenous ME and NIL-derived PRF.
Our recent data have shown that SAL is present in extracts of the posterior pituitary gland obtained from ruminants also, and it also has PRL-releasing activity both in vivo and in vitro, as in rodents [34] . Evidence has also been obtained that SAL is involved in the regulatory process for secretion of PRL, not only in male and female calves, but also in cows [35] . The potency of the PRLreleasing response to SAL differs with the physiological status of cattle. Furthermore, the mechanism(s) by which SAL releases PRL is different from the mechanism of action of TRH. In ruminants, the secretion of PRL is also under the inhibitory control of DA, and SAL does not antagonize the DA receptor's action [36, 37] . These data support the assumption that this endogenous compound could have more general involvement in the regulation of pituitary PRL secretion and it is synthesized in different species also.
There are studies which clearly suggest that SAL may be involved in alcohol addiction [38] and it may also contributes to the etiology of neuropathology of chronic alcoholism [39] . Synthesis of SAL from DA and acetaldehyde (the major metabolic product of ethanol) suggests its involvement in alcohol addiction also [40] . This is supported by the observation that urinary concentrations of SAL have been found to be significantly higher in chronic alcoholics than in non-alcoholic control subjects [41, 42] . Also the local concentration of this isoquinoline derivative increases in rat brain during ethanol intoxication [43] .
In this and in general respects, a recent observation of Ewing's laboratory [44] is noteworthy. By use of micellar electrokinetic chromatography coupled with amperometric electrochemical detection biogenic amines and metabolites that are thought to be involved in the response to alcohol have been determined within the head of fruit fly (Drosophila melanogaster). Besides DA, N-acetyl-DA, octopamine, and N-acetyloctopamine, SAL has also been detected and quantified in three different microdissected brain regions, i.e. in the central brain, in the optic lobes, and in the posterior superiormedial protocerebrum region [45] . It is clear that discussion of insect endocrinology is beyond of the topic of this review, but it should be mentioned that the existence of counterparts of several neuropeptides, including PRL, in Drosophila melanogaster is already proved [46, 47] . The significance of these findings needs to be further investigated.
Possible physiological role of salsolinol
Analysis of SAL concentrations in NIL revealed parallel increases with plasma PRL in lactating rats exposed to a brief (10 min) suckling stimulus after 4-h separation (Fig. 2b, c) . SAL is sufficiently potent in vivo to account for the massive discharge of PRL that occurs after physiological stimuli (i.e. suckling). At the same time, it was without effect on the secretion of other pituitary hormones. SAL, therefore, seems to be a selective stimulator of PRL secretion in vivo [25] . Based on all of these data it is clear that this newly discovered endogenous compound could be involved in the regulation of pituitary PRL secretion.
We have also found that SAL can elevate PRL release, although to a lesser extent, in pituitary cell cultures and in hypophysectomized rats bearing AL transplants under the kidney capsule [25] . Lack of interference of SAL with [3H]-spiperone binding to AL homogenates [25] indicates that SAL does not act on the D2 DA receptors that are exclusively present on lactotropes. Moreover, [3H]-SAL can bind specifically to homogenate of AL obtained from lactating rats [48] . Parallel to the elevation of plasma PRL, SAL induces a significant decrease of cAMP concentration in the ME. In contrast, SAL injection results in a slight increase of cAMP at the level of the AL of the pituitary gland [49] .
Taken together, these data clearly suggest that SAL is synthesized in situ in the hypothalamic-ME, and in the hypothalamic-NIL systems. Furthermore, they also suggest that mediation of SAL's effect requires plasma membrane binding that is supposedly coupled with specific second messenger systems. On the basis of all these data it is clear that this newly discovered endogenous compound could be involved in the regulation of pituitary PRL secretion [50] .
It has been also shown that another isoquinoline derivative, 1-methyldihydroisoquinoline (1MeDIQ, Fig. 3 ), which is a structural analogue of SAL, can dose-dependently inhibit the in-vivo PRL-releasing effect of SAL. Moreover, 1MeDIQ can inhibit the elevation of plasma PRL induced by physiological stimuli, for example suckling or different stressful situations also [51, 52] . These observations, although indirectly, strongly support our previous assumption that SAL may be a physiologically important prolactoliberin. At the same time, 1MeDIQ has psycho-stimulant action which is fairly similar to the effect of amphetamine, i.e. it induces release of catecholamine, including DA from nerve terminals [53] . Interestingly enough, there is an obvious interaction between amphetamine and SAL on DA levels in the atrium and on PRL release by the AL (Fig. 4) .
Effect of salsolinol on catecholamine release from peripheral organs
Besides its PRL-releasing activity, SAL can significantly reduce the DA content in peripheral, sympathetically innervated organs, for example the atrium, spleen, liver, ovaries, vas deferens, and salivary gland, in a dose and time-dependent manner, without having any effect on the concentration of norepinephrine (NE) [54, 55] . This DA-depleting effect of SAL in the atrium is shown in Fig. 4 . More interestingly, this effect of SAL is completely prevented by amphetamine pretreatment (Fig. 4) . It is, therefore, clear that a mutual interaction between SAL and amphetamine exists not only on PRL release from the AL of the pituitary gland but their interaction in the catecholamine ''metabolism'' of sympathetic nerve terminals is also obvious.
As has already been remarked above, 1MeDIQ can prevent SAL-induced PRL response and has a psychostimulant action which is fairly similar to the effect of amphetamine, i.e. induces an increase in plasma catecholamine concentrations [53] .
Stress, drugs, alcohol, and salsolinol
Stress situations [51] [52] [53] 56] , psycho-stimulant drugs [57] , for example amphetamine, and alcohol [58] are known to affect pituitary PRL secretion.
We have also provided evidence that 1MeDIQ, the structural analogue of SAL, can profoundly inhibit not only suckling, but also immobilization (IMO) and formalinstress-induced PRL release without having any effect on corticosterone secretion. The 1MeDIQ-induced reduction in PRL response to IMO was dose-dependent. These results suggest that SAL can have pivotal involvement in the regulation of PRL release induced by either physiological (suckling) or environmental (stress) stimuli. On the other hand, on the basis of the similarity between plasma catecholamines and PRL responses to stressors, we have investigated the question of whether SAL plays any role in the regulation of plasma catecholamine release at rest and of the release of catecholamines induced by IMO. SAL did ) and amphetamine (AMPH, 5 mg/kg i.p.) (20 and 15 min before sampling, respectively), alone or in combination, on plasma prolactin (PRL), dopamine (DA), and norepinephrine (NE) levels and on NE/DA ratios in the atria of male rats; n = 6, mean ± SEM; *P \ 0.05, compared with the control; significant interaction between SAL and amphetamine labeled
Reprod Med Biol not affect baseline levels of catecholamines; however, it did inhibit IMO-induced release of these compounds. Thus, this study has shown for the first time that SAL is not only a PRF but is also a potent inhibitor of stress-induced release of epinephrine and NE [51] [52] [53] 56] .
As far as amphetamine is concerned, detailed and parallel analysis of the effect on the level of plasma PRL and peripheral tissue catecholamines seems to be critical, because amphetamine is one of the best-characterized indirect DA agonists, i.e. it significantly elevates extraterminal DA levels and, consequently, increases DAerg tone on DA receptors. Interestingly enough, very little has been known about the effect of amphetamine on peripheral sympathetic terminals (i.e. plasma NE and E). Parallel measurements of catecholamine levels at the hypothalamopituitary system and plasma PRL (reflecting to the ''central'' DA system) and plasma levels of catecholamines (reflecting to the response occurs in sympatho-adrenal system) have been shown in Fig. 4 .
Parallel with the neuroendocrine and peripheral catecholaminergic characteristics of SAL and 1MeDIQ, psychopharmacological interaction between several TIQs and amphetamine have also been investigated. Our preliminary (unpublished) observations have shown that neither SAL nor 1Met-DIQ affects locomotor activity of naive rats but 1Met-DIQ and other TIQ compounds can strongly antagonize amphetamine-induced hypermotility of the same animals, which was especially obvious for the (non-resting) motion periods (unpublished). Therefore, an equally important objective of our future studies should be to obtain information about the changes in signaling cascades at the level of both the hypothalamo-hypophysial and the peripheral sympathetic system after amphetamine, 1MeDIQ, and SAL administration. These investigations may provide new insight into treatment for drug abuse, and may help to find new daytime sedative or stress-releasing agents.
In addition to the effect of SAL on pituitary stress responses and on amphetamine induced catecholamine release, another very important context of the role of SAL has already been suggested (vide supra), namely, in the acute and chronic effects of alcohol. Alcohol has a wide range of effects on different brain areas, which, among other effects, significantly affect or modulate catecholamine neurotransmitter systems [59] . Moreover, there are several reports providing evidence for the high level of PRL in alcoholic men and women [58] . Alcohol-induced hyperprolactinemia has also been demonstrated in laboratory animals [58] . Acute PRL-releasing activity of ethanol in male and lactating female rats can be seen in Fig. 5 . Interestingly enough, the same dose of ethanol (500 mg/kg bw in 2 ml) injected intraperitoneally (i.p.) induced a significantly higher PRL response in male rats than in lactating female rats. Chronic administration of ethanol increases plasma PRL levels and enhances estradiol's mitogenic action on the lactotropes of the pituitary gland [58] . It has been also shown that acetaldehyde, the first metabolite of alcohol, is responsible for some behavioral and neurochemical effects of alcohol [60, 61] . As we have already mentioned, when acetaldehyde reacts with catecholamines, these reactions produce the so-called TIQs, and more importantly the condensation product of DA will be SAL [62, 63] .
The effects of acute stress and acute and chronic alcohol consumption on sperm motility and reproductive endocrinology have been extensively investigated in rodents and human subjects. Acute restraint stress, for example, reduces sperm motility, starting after 30 min. It also induces a significant elevation of plasma adrenocorticotrophic hormone (ACTH), PRL, corticosterone, and progesterone, and reduces follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and inhibin [64] . Genital dysfunction and testosterone deficiency occur frequently in Parkinson's disease and are a typical non-motor symptom of the disorder. Seven days after treatment of mice with the Parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a marked decrease in testosterone plasma levels in MPTP-treated mice can be detected. Such testosterone loss occurred concomitantly with loss of Leydig cells and the presence of altered morphology in the interstitium. The loss of Leydig cells is accompanied by a marked decrease in tyrosine hydroxylase (TH) immunostaining and TH protein in the interstitium [65] . It is also well established that ethanol inhibits the hypothalamo-pituitary-testes axis and reduces the serum testosterone level [66, 67] . Such general coincidences have prompted us to study the effect of SAL on testosterone production both in vivo and in vitro. As shown in Fig. 6 , bilateral injection of SAL in vivo into the testis and SAL treatment of either right or left testis in culture dramatically reduced testosterone concentration in the serum and in the culture medium, respectively. Treatment with domperidone, a D2 DA receptor inhibitor, alone, has no effect, and cannot prevent SAL-induced testosterone depletion from the testis.
Epilogue
The involvement of peripheral DA and SAL in the systemic disorders discussed above are still poorly understood. Clearly, much remains to be done. There is no doubt that both peripheral and central DA systems are sensitive to environmental effects [68] . Concomitant changes in the peripheral DA and SAL system must make a significant contribution to these homeostatic events. Given a possible future use of such compounds, it is clear that better understanding of the integrated role of DA and SAL is a critical aspect in respect of the whole organism. The in-vitro effect of SAL and DOM alone and in combination on the levels of testosterone released into the medium from either the right or the left testis incubated in vitro [69] . n = 7, mean ± SEM; *P \ 0.05, compared with NaCl-treated control values
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